MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) Annual Meeting 2016
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Presentations of Clinical Data at Upcoming American Society
of Hematology (ASH) Annual Meeting 2016
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Oral presentations on proprietary antibody programs MOR208 and MOR202
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today
announced upcoming presentations of data on the Company's proprietary hemato-
oncological programs MOR208 and MOR202 at the 58th American Society of
Hematology (ASH) Annual Meeting, being held December 3-6, 2016 in San Diego,
California/USA.
"We are pleased that updated clinical trial results with our antibodies MOR208
and MOR202 in patients with B-cell malignancies and multiple myeloma,
respectively, will be shown at the upcoming ASH conference as oral
presentations," commented Dr. Arndt Schottelius, Chief Development Officer of
MorphoSys AG. "We expect this will further demonstrate the potential of our
proprietary development candidates for patients suffering from those hemato-
oncological malignancies that have a particularly high unmet medical need."
Abstracts from MorphoSys's proprietary programs accepted for presentation at ASH
2016:
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma
(NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL
Subgroups of a Phase IIa Study
The oral presentation will include updated clinical results, in particular with
respect to duration of responses, from a phase 2a MOR208 monotherapy trial in
adult patients with relapsed/refractory NHL including DLBCL and iNHL.
Abstract #623
Session Name: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other
Aggressive B-Cell Non-Hodgkin Lymphomas) - Results from Prospective Clinical
Trials: Novel Agents
Session Date: Monday, December 5, 2016
Session Time: 7:00am-8:30am (PST) (4:00pm-5:30pm CET)
Presentation Time: 8:00am PST (5:00pm CET)
Room: San Diego Convention Center, Room 6B
A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with
Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple
Myeloma
The oral presentation will include updated safety and efficacy results from the
ongoing phase 1/2a MOR202 dose-escalation study in pre-treated multiple myeloma
patients. Results will in particular include maturing data from the MOR202
8mg/kg patient cohorts in combination with lenalidomide and pomalidomide as well
as first results from the highest dose cohorts of 16mg/kg MOR202 in combination
with lenalidomide and pomalidomide.
Abstract #1152
Session Name: 653. Myeloma: Therapy, excluding Transplantation: Immunotherapy
Session Date: Monday, December 5, 2016
Session Time: 4:30pm-6:00pm (PST) (December 6, 2016, 1:30am-3:00am CET)
Presentation Time: 5:45pm (PST) (December 6, 2016, 2:45am CET)
Room: San Diego Convention Center, Hall AB
Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208
in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia
(CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-
Resistant Clones
The poster presentation will include safety and efficacy results from the
ongoing phase 2 investigator initiated trial (IIT) of MOR208 in combination with
lenalidomide or ibrutinib in CLL.
Abstract #4386
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00pm-8:00pm (PST) (December 6, 2016, 3:00am-5:00am CET)
Location: San Diego Convention Center, Hall GH
In addition to the presentations, all abstracts will be published online in the
December 1, 2016 supplemental volume of Blood.
Additional information can be found at www.hematology.org, including the
abstracts.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated,
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/2054078/768898.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 03.11.2016 - 14:41 Uhr
Sprache: Deutsch
News-ID 504832
Anzahl Zeichen: 6951
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 289 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) Annual Meeting 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
